Joseph Gilliam Sells 4,502 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS) COO Joseph Gilliam sold 4,502 shares of the firm’s stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $124.65, for a total value of $561,174.30. Following the completion of the transaction, the chief operating officer owned 92,366 shares in the company, valued at approximately $11,513,421.90. This trade represents a 4.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Glaukos Stock Down 4.7%

Shares of NYSE:GKOS opened at $119.96 on Friday. The stock has a 50-day simple moving average of $110.53 and a 200-day simple moving average of $96.23. The stock has a market capitalization of $6.89 billion, a P/E ratio of -77.89 and a beta of 0.67. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $161.78. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.47 and a current ratio of 5.20.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.11. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The firm had revenue of $133.54 million for the quarter, compared to analyst estimates of $122.55 million. During the same quarter last year, the firm posted ($0.28) earnings per share. Glaukos’s revenue for the quarter was up 38.1% compared to the same quarter last year. Equities analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current year.

Institutional Trading of Glaukos

Hedge funds and other institutional investors have recently modified their holdings of the business. Smartleaf Asset Management LLC boosted its holdings in Glaukos by 16.2% in the second quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 136 shares during the last quarter. UMB Bank n.a. increased its holdings in Glaukos by 102.6% during the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 158 shares during the last quarter. Park Place Capital Corp raised its position in shares of Glaukos by 68.4% in the 2nd quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock valued at $41,000 after purchasing an additional 162 shares in the last quarter. Focus Partners Wealth raised its position in shares of Glaukos by 6.9% in the 3rd quarter. Focus Partners Wealth now owns 2,714 shares of the medical instruments supplier’s stock valued at $202,000 after purchasing an additional 176 shares in the last quarter. Finally, AQR Capital Management LLC boosted its stake in shares of Glaukos by 2.6% during the 1st quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock valued at $766,000 after buying an additional 198 shares during the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

GKOS has been the subject of several recent research reports. Wells Fargo & Company increased their price target on Glaukos from $120.00 to $122.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. JPMorgan Chase & Co. upped their target price on Glaukos from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, October 30th. The Goldman Sachs Group reiterated a “buy” rating and issued a $138.00 target price on shares of Glaukos in a research note on Friday, January 9th. Stifel Nicolaus boosted their price target on Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, UBS Group upped their price target on Glaukos from $140.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, December 23rd. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $131.38.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.